On March 20, 2018, the Food and Drug Administration approved brentuximab vedotin for injection,for intravenous use,to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
Are you looking for or in search of FDA approved “brentuximab vedotin for injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Breast Cancer. Need Access of brentuximab vedotin for injection, get in touch with our healthcare professional.
brentuximab vedotin for injection is a CD30-directed antibody-drug conjugate indicated for treatment of patients with:
• Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.
• Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.